Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma

Next Previous
Trial Profile

Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elimusertib (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Cervical cancer; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Lymphadenopathy; Mouth neoplasm; Oropharyngeal cancer; Salivary gland cancer; Skin cancer; Squamous cell cancer
  • Focus Adverse reactions; Biomarker

Most Recent Events

  • 29 Jul 2026 Planned End Date changed from 11 Dec 2025 to 14 Jan 2027.
  • 29 Jul 2026 Actual primary completion date changed from 27 Nov 2024 to 22 Jul 2025.
  • 13 Dec 2024 Planned End Date changed from 27 Nov 2024 to 11 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top